Employer Active
Job Alert
You will be updated with latest job alerts via emailJob Alert
You will be updated with latest job alerts via emailRoche fosters diversity equity and inclusion representing the communities we serve. When dealing with healthcare on a global scale diversity is an essential ingredient to success. We believe that inclusion is key to understanding peoples varied healthcare needs. Together we embrace individuality and share a passion for exceptional care. Join Roche where every voice matters.
Roche fosters diversity equity and inclusion representing the communities we serve. When dealing with healthcare on a global scale diversity is an essential ingredient to success. We believe that inclusion is key to understanding peoples varied healthcare needs. Together we embrace individuality and share a passion for exceptional care. Join Roche where every voice matters.
Postdoctoral researcher in computational oncology: integrative analysis of multimodal data in triple negative breast cancer
Who we are: Institut Roche is a noncommercial affiliate of Roche located in Boulogne near Paris France dedicated to the development and management of preclinical and translational collaborative projects between Roche and the academic ecosystem. Institut Roches team includes almost exclusively PhDs with expertise ranging from immunology to neuroscience and oncology and several data and analytics experts. Institut Roche boasts strong connections to the wide Roche ecosystem in particular the research centers in Basel (pRED) and South San Francisco (Genentech). Roche is a global leader in pharmaceutical research pioneer in the field of immunooncology and second top pharma R&D investor worldwide.
The position: The postdoctoral researcher will be in charge of integrative analysis for the Cassiopeia project a collaborative project taking place at Institut Curie in Paris France. The goal of Cassiopeia project is to create a significant paradigm shift in the clinical care of patients with TripleNegative Breast Cancer (TNBC). TNBC is frequently diagnosed in young women with an incidence of 9000 to 15000 new cases annually and is associated with a poor prognosisa survival rate of 60. These patients face a higher risk of early metastatic recurrence and have a shorter overall survival compared to other breast cancer subtypes. Over the last decade chemotherapy has been the sole systemic therapeutic option offering limited efficacy. There remains a critical need for the identification of biomarkers to pinpoint patients at high risk of relapse and those who are resistant to treatment.
The postdoctoral researcher will be leading the integrative analysis of multimodal data generated in Cassiopeia including scRNAseq spatial transcriptomics clinical data multiplex IHC radiomic TCRseq and ctDNA. The position will require building a clinically relevant strategy for multimodal feature selection integration and response association/prediction. The postdoctoral researcher will be tasked with maintaining and strengthening collaboration with internal teams in Basel and South San Francisco on the Cassiopeia project and leveraging computational skills across the entire organization. The overarching goal of the project is to better understand and overcome resistance to therapy in triple negative breast cancer.
Who you are:
At Roche more than 100000 people across 100 countries are pushing back the frontiers of healthcare. Working together weve become one of the worlds leading researchfocused healthcare groups. Our success is built on innovation curiosity and diversity.
Roche is an Equal Opportunity Employer.
At Roche more than 100000 people across 100 countries are pushing back the frontiers of healthcare. Working together weve become one of the worlds leading researchfocused healthcare groups. Our success is built on innovation curiosity and diversity.
Roche is an Equal Opportunity Employer.
Full-Time